September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Chemotherapy with biological agents and ocular side effects
Author Affiliations & Notes
  • Dimosthenis Mantopoulos
    Department of Ophthalmology and Visual Science, The Ohio State University, Columbus, Ohio, United States
  • Elaine Michele Binkley
    Department of Ophthalmology and Visual Science, The Ohio State University, Columbus, Ohio, United States
  • Anne L Kunkler
    Department of Ophthalmology and Visual Science, The Ohio State University, Columbus, Ohio, United States
    Medical School, The Ohio State University, Columbus, Ohio, United States
  • Kari Kendra
    Division of Medical Oncology, The Ohio State University, Columbus, Ohio, United States
  • Colleen M Cebulla
    Department of Ophthalmology and Visual Science, The Ohio State University, Columbus, Ohio, United States
  • Footnotes
    Commercial Relationships   Dimosthenis Mantopoulos, None; Elaine Binkley, None; Anne Kunkler, None; Kari Kendra, None; Colleen Cebulla, None
  • Footnotes
    Support  Ohio Lions Eye Research Foundation. Research reported in this publication was supported by the National Eye Institute of the National Institutes of Health under Award Number K08EY022672. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 298. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Dimosthenis Mantopoulos, Elaine Michele Binkley, Anne L Kunkler, Kari Kendra, Colleen M Cebulla; Chemotherapy with biological agents and ocular side effects. Invest. Ophthalmol. Vis. Sci. 2016;57(12):298.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The biological agents are substances derived from living organisms that have recently found wide applications in medicine. However, they are a relatively new category of drugs and our knowledge about their side effects is limited. This retrospective, observational study reviews the ocular sequelae of these agents in patients who presented to the ophthalmology clinic of our tertiary center.

Methods : Approval was obtained from the Institutional Review Board. A search of the electronic medical record was conducted to identify adult patients being treated with biologic agents for various types of malignancy who presented for ophthalmic evaluation. The patients were either referred for routine screening or presented with visual/ocular complaints between 1/1/2010 and 2/2/2015 (61 months). For the current study we analyzed the charts of patients who were treated with biologic agents including: interferon, leukine, ipilimumab, mirvetuximab, soravtensine and trastuzumab.

Results : From the 1000 charts that were analyzed, 11 patients had ocular side effects while on biologic agents and met the inclusion criteria. Ten of these patients (10/11 or 91%) were symptomatic. The most frequent visual complaint was mild to moderate vision loss (8/10 or 80%). The most common medication in this category was interferon (6/11 or 55%) and the most common finding in these patients was cotton wool spots (4/6 or 67%). For patients with adequate follow up, discontinuation of the medication lead to resolution of the symptoms in the majority of cases (6/8 or 75%).

Conclusions : The current study describes the ocular symptoms and signs in patients treated systemically with biologic agents at our university hospital. In the majority of cases, discontinuation of the medication lead to resolution of symptoms. Further studies are needed to elucidate the incidence and pathophysiology of these side effects, something that could lead to optimal screening and treatment guidelines for these patients.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×